XML 45 R35.htm IDEA: XBRL DOCUMENT v3.21.2
Segment Information (Tables)
 9 Months Ended
Sep. 30, 2021
Segment Reporting [Abstract]  
Reportable Segment Information
 Three Months EndedNine Months Ended
September 30,September 30,
(DOLLARS IN MILLIONS)2021202020212020
Net sales:
Nourish$1,662 $712 $4,638 $2,174 
Health & Biosciences618 31 1,683 99 
Scent580 525 1,699 1,541 
Pharma Solutions211 — 605 — 
Consolidated$3,071 $1,268 $8,625 $3,814 
Segment Adjusted Operating EBITDA
Nourish$327 $148 $921 $466 
Health & Biosciences151 10 469 29 
Scent130 118 375 323 
Pharma Solutions40 — 131 — 
Total648 276 1,896 818 
Depreciation & Amortization(297)(83)(861)(244)
Interest Expense(74)(35)(216)(99)
Other income (expense), net26 (10)44 (5)
Frutarom Integration Related Costs (a)(1)(2)(3)(9)
Restructuring and Other Charges (6)(1)(34)(8)
Gains (Losses) on Sale of Assets 1 (1)1 (2)
Shareholder Activism Related Costs (b)— — (7)— 
Business Divestiture Costs (c)(16)— (21)— 
Employee Separation Costs (d)(22)— (28)— 
Frutarom Acquisition Related Costs (e)— (1)— (1)
Compliance Review & Legal Defense Costs (f)— (1)— (2)
N&B Inventory Step-Up Costs 14 — (363)— 
N&B Transaction Related Costs (g)— (8)(91)(24)
N&B Integration Related Costs (h)(23)(29)(77)(62)
Income Before Taxes$250 $105 $240 $362 
_______________________
(a)Represents costs related to the integration of the Frutarom acquisition. For 2021, costs primarily related to performance stock awards. For 2020, costs primarily related to advisory services, retention bonuses and performance stock awards.
(b)Represents shareholder activist related costs, primarily professional fees.
(c)Represents costs related to the Company's planned sales of businesses, primarily legal and professional fees.
(d)Represents costs related to severance, including accelerated stock compensation expense, for certain employees and executives who have been separated or will separate from the Company.
(e)Represents transaction-related costs and expenses related to the acquisition of Frutarom. For 2020, amount primarily includes earn-out payments, net of adjustments, amortization for inventory "step-up" costs and transaction costs principally related to the 2019 Acquisition Activity.
(f)Costs related to reviewing the nature of inappropriate payments and review of compliance in certain other countries. In addition, includes legal costs for related shareholder lawsuits.
(g)Represents transaction costs and expenses related to the transaction with N&B, primarily includes legal and professional fees.
(h)Represents costs primarily related to advisory services for the integration of the transaction with N&B, primarily consulting fees.
Net Sales by Destination of Product Delivery
Net sales, which are attributed to individual regions based upon the destination of product delivery, were as follows:
 Three Months Ended September 30,Nine Months Ended September 30,
(DOLLARS IN MILLIONS)2021202020212020
Europe, Africa and Middle East$1,084 $481 $3,041 $1,487 
Greater Asia696 283 1,990 868 
North America925 321 2,608 925 
Latin America366 183 986 534 
Consolidated$3,071 $1,268 $8,625 $3,814 
 Three Months Ended September 30,Nine Months Ended September 30,
(DOLLARS IN MILLIONS)2021202020212020
Net sales related to the U.S.$860 $286 $2,390 $825 
Net sales attributed to all foreign countries2,211 982 6,235 2,989